Trovagene’s PCM-075 Increases Zytiga’s Punch Against Prostate Cancer, Studies Show

Trovagene’s PCM-075 Increases Zytiga’s Punch Against Prostate Cancer, Studies Show
Trovagene’s enzyme inhibitor PCM-075 increases the punch of the prostate cancer therapy Zytiga (abiraterone), preclinical-trial studies show. PCM-075 is a selective polo-like kinase 1 (PLK1) inhibitor. It inhibits a protein called PLK1, whose levels are particularly high in cancer cells and which doctors have associated with poor patient outcomes. Studies have shown that inhibiting PLK1 triggers the death of tumor cells. Zytiga is the world's leading androgen deprivation therapy for metastatic castration-resistant prostate cancer, or mCRPC. It decreases levels of male
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *